文献速递泌尿生殖MRUS

单侧mpMRI可见病灶患者同侧半腺体穿刺可能低估癌症负荷

Ipsilateral hemigland prostate biopsy may underestimate cancer burden in patients with unilateral mpMRI-visible lesions.
PubMed 文献 · Abdom Radiol (NY) · 2022-12-17

本研究纳入212例单侧mpMRI可见前列腺内病灶患者,行MRI/TRUS融合靶向穿刺联合系统穿刺。结果显示43.4%患者检出临床显著前列腺癌,其中81.5%仅同侧受累。仅在同侧半腺体行减少穿刺方案(TBx+IBx)的敏感度为92.4%,较TBx+SBx低估至少8%的csPCa。

要点

  • 单侧mpMRI可见病灶患者中,81.5%的csPCa仅同侧受累,但7.6%仅对侧受累。
  • TBx+IBx方案csPCa敏感度92.4%,仍低估至少8%的癌症负荷。
  • TBx+CBx方案csPCa敏感度91.3%,与TBx+IBx接近。

局限性

  • 原文未明确报告研究设计类型(回顾性或前瞻性)及中心数。
  • 样本量212例,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To evaluate the cancer detection rates of reduced-core biopsy schemes in patients with unilateral mpMRI-visible intraprostatic lesions and to analyze the contribution of systematic biopsy cores in clinically significant prostate cancer (csPCa) detection.

METHODS: 212 patients with mpMRI-visible unilateral intraprostatic lesions undergoing MRI/TRUS fusion-guided targeted biopsy (TBx) and systematic biopsy (SBx) were included. Cancer detection rates of TBx + SBx, as determined by highest Gleason Grade Group (GG), were compared to 3 reduced-core biopsy schemes: TBx alone, TBx + ipsilateral systematic biopsy (IBx; MRI-positive hemigland), and TBx + contralateral systematic biopsy (CBx; MRI-negative hemigland). Patient-level and biopsy core-level data were analyzed using descriptive statistics with confidence intervals. Univariable and multivariable logistic regression analysis was conducted to identify predictors of csPCa (≥ GG2) detected in MRI-negative hemiglands at p < 0.05.

RESULTS: Overall, 43.4% (92/212) of patients had csPCa and 66.0% (140/212) of patients had any PCa detected by TBx + SBx. Of patients with csPCa, 81.5% had exclusively ipsilateral involvement (MRI-positive), 7.6% had only contralateral involvement (MRI-negative), and 10.9% had bilateral involvement. The csPCa detection rates of reduced-core biopsy schemes were 35.4% (75/212), 40.1% (85/212), and 39.6% (84/212) for TBx alone, TBx + IBx, and TBx + CBx, respectively, with detection sensitivities of 81.5%, 92.4%, and 91.3% compared to TBx + SBx.

CONCLUSION: Reduced-core prostate biopsy strategies confined to the ipsilateral hemigland underestimate csPCa burden by at least 8% in patients with unilateral mpMRI-visible intraprostatic lesions. The combined TBx + SBx strategy maximizes csPCa detection.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Phelps, Yilmaz, Harmon, et al. Ipsilateral hemigland prostate biopsy may underestimate cancer burden in patients with unilateral mpMRI-visible lesions. Abdom Radiol (NY). 2022. PMID: 36526922. doi:10.1007/s00261-022-03775-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。